Bristol-myers Squibb Compnay

Rita Civiello

Nicholas A Meanwell

Kuo-Long Yu

Xiaojun Han

Xiangdong Alan Wang

Keith D Combrink

Yi Zhang

Hatice Belgin Gulgeze

John E Macor

Guanglin Luo

Gene Michael Dubowchik

Prasad V Chaturvedula

Ny Sin

Graham S Poindexter

George O Tora

Andrew P Degnan

Ling Chen

Brian Lee Venables

Jan Willem Thuring

Xiang Jun J Jiang

Zhiwei Yin

Pratik Devasthale

Guohua Zhao

Michael Frederick Parker

Bradley C Pearce

Xiang-Yang Ye

Kumaravel Selvakumar

Suresh Dhanusu

Mark R Krystal

George N Karageorge

Swanee E Jacutin-Porte

Leatte R Guernon

Shikha Vig

Kathleen F Kadow

Palanikumar Balasubramanian

Christopher W Cianci

Yaxiong Sun

Bradley C Pearc

Charles Mark Conway

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Anti-migraine spirocycles

The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I) 

Anti-migraine treatments

Calcitonin gene related peptide receptor antagonists

The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.

Substituted benzimidazole antiviral agents

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents

Heterocyclic substituted 2-methyl-benzimidazole antiviral agents

The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.

Benzimidazolone antiviral agents

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides imidazopyridine and imidazopyrimidine derivatives (Formula I) for the treatment of respiratory syncytial virus infection.

Imidazopyridine and imidazopyrimidine antiviral agents

Growing community of inventors

Killingworth, CT, United States of America

Rita Civiello